{"id":"f5c04936-20ae-42c6-8077-87ffb0ebcc32","kind":"institutions","code":"UB-I8618","name":"Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership)","nameBasis":"transliterated","summary":"Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), an industry investment fund focused on healthcare.","description":"Yuanxi Haihe (Tianjin) Biomedical Industry Fund Partnership (Limited Partnership), an industry investment fund focused on healthcare.","country":null,"category":null,"originalName":"元希海河（天津）生物医药产业基金合伙企业（有限合伙）","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:28:22.214Z","englishUpdatedAt":"2026-10-15T21:43:23.735Z","reviewedAt":"2026-10-15T21:43:23.735Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"6b4a436601e5f21936636a1b9dd36c156c38ea4c4499c30a063663c41cc4d0a8","companyId":null,"foundedYear":null,"logoUrl":null,"originalText":"元希海河（天津）生物医药产业基金合伙企业（有限合伙），聚焦医疗健康领域的产业投资基金。","sources":[],"related":[{"id":"48c7fbb5-da1d-4d8f-8891-16287b8388df","kind":"news","code":"48c7fbb5-da1d-4d8f-8891-16287b8388df","name":"iRegene raises RMB 260 million in Series C+ financing","nameBasis":"translated-title","summary":"On 2026-07-02, according to Xiniu Data, iRegene completed Series C+ financing, raising RMB 260 million. Investors were lead investor Chengdu Ke Venture Capital, participating investor Zhongxinjian Investment Ben, participating investor Xi Venture Capital, participating investor Dingtaixing, participating investor Xinjiye, participating investor Hongyi Capital, participating investor Yuanxihaihe (Tianjin) Biotechnology Pharmaceutical Industry Fund Partnership (Limited Partnership). The company is a developer of chemically induced cell therapy drugs.","description":"","country":null,"category":null,"originalName":"睿健医药完成C+融资，金额2.60亿人民币","eventDate":"2026-07-02T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-15T17:18:19.314Z","englishUpdatedAt":"2026-10-20T18:21:37.336Z","reviewedAt":"2026-10-20T18:21:37.336Z","snapshotAt":"2026-10-20T18:19:32.670Z","sourceHash":"952c547ad5eb57bf8d1dbe53be1cab5e2540393b32284532c5147f6372db89f6","companyId":"c6f40f74-5248-4720-8404-fd1e03022e90","foundedYear":null,"logoUrl":null,"path":"/news/48c7fbb5-da1d-4d8f-8891-16287b8388df"}],"path":"/institutions/yuanxihaihe-tianjin-biotechnology-pharmaceutical-industry-fund-partnership-limited-partnership","displayName":"元希海河（天津）生物医药产业基金合伙企业（有限合伙）","displayNameLang":"zh","structured":{"city":null,"country":"China (mainland)","location":null,"role":null,"category":null,"company":null},"definition":"元希海河（天津）生物医药产业基金合伙企业（有限合伙） is an industry fund based in China (mainland) with 1 recorded investment.","summaryBasis":"translated","thin":false,"canonical":"https://uniquebase.ai/institutions/yuanxihaihe-tianjin-biotechnology-pharmaceutical-industry-fund-partnership-limited-partnership"}